Holen Sie sich die Stockscreener-App
9.94
3.21%
-0.33
Vorhandelsmarkt:
9.92
-0.02
-0.20%
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Form 4 Zevra Therapeutics Inc: Neil F. McFarlane (Director, President and CEO) For: 10 October - Investing.com Canada
Zevra Therapeutics president and CEO sells $224,948 in stock - Investing.com
A 20,000-share sale was reported by Zevra Therapeutics (ZVRA) director Neil F. McFarlane. - Stock Titan
Diluted net income available to common stockholders of Zevra Therapeutics, Inc. – HAN:1GDA - TradingView
Zevra Therapeutics, Inc. Stock (ZVRA)Quote Nasdaq - marketscreener.com
Zevra Therapeutics at Cantor conference: growth, cash and rare-disease bets - Investing.com India
ZVRA: Expanding rare disease reach with strong financials, robust IP, and accelerating global growth - TradingView
Zevra Therapeutics at Cantor conference: growth, cash and rare-disease bets - Investing.com Canada
Why (ZVRA) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Zevra Therapeutics to Present at Upcoming Investor Conferences - Yahoo Finance
Zevra Therapeutics Presents Long-Term Real-World Data Supporting MIPLYFFA in Niemann-Pick Disease Type C at SSIEM Annual Symposium - Quiver Quantitative
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - Barchart.com
Zevra Therapeutics to Present New Long-Term Real-World Data on MIPLYFFA® in Niemann-Pick Disease Type C (NPC) at the 2026 SSIEM Annual Symposium - The Manila Times
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Four new Zevra employees receive stock options that vest over four years - Stock Titan
H.C. Wainwright Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $26 - Moomoo
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright - MarketBeat
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy By Investing.com - Investing.com Canada
ZVRA Reiterated by HC Wainwright & Co. -- Price Target Maintained at $26 - GuruFocus
H.C. Wainwright reiterates Zevra Therapeutics stock rating at buy - Investing.com
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - marketscreener.com
Zevra Therapeutics (ZVRA) insider sells 42,666 shares - Stock Titan
Zevra Therapeutics Insider Sold Shares Worth $474,774, According to a Recent SEC Filing - Yahoo Finance
Price-Driven Insight from (ZVRA) for Rule-Based Strategy - Stock Traders Daily
Zevra Therapeutics (ZVRA) insider files to resell RSU shares via broker - Stock Titan
Woodline Partners discloses 4.8M-share Zevra Therapeutics (ZVRA) ownership position - Stock Titan
ZVRA Q2 2026 Earnings: EPS Beats Estimates by 27.85% as Bottom-Line Strength ContinuesLow Estimate Range - vinanet.vn
Price to earnings forward of Zevra Therapeutics, Inc. – FWB:1GDA - TradingView
Insider Move: Corey M. Watton Exercises Options, Realizing $77K At Zevra Therapeutics - Benzinga
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zevra Therapeutics, Inc.ZVRA - PR Newswire
Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics (NASDAQ:ZVRA) Director Sells $138,375.00 in Stock - MarketBeat
Dimensional Fund Advisors LP Acquires 400,336 Shares of Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Nigeria
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com Canada
Bronstein, Gewirtz & Grossman, LLC Encourages Zevra Therapeutics - The National Law Review
Zevra Therapeutics at Canaccord Genuity: growth plan widens By Investing.com - Investing.com UK
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Connect - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Zevra Therape - The National Law Review
Hennion & Walsh Asset Management Inc. Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
HC Wainwright Has Positive Outlook for ZVRA FY2027 Earnings - marketbeat.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Zevra Therapeutics, Inc. (ZVRA) And Encourages Shareholders to Reach Out - ACCESS Newswire
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - Sahm
Maxim Group Maintains Zevra Therapeutics(ZVRA.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Zevra Therapeutics, Inc. (ZVRA) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Zevra Therapeutics, Inc. (ZVRA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - accessnewswire.com
ZVRA Maintained by Guggenheim -- Price Target Lowered to $23.00 - GuruFocus
Zevra Therapeutics (NASDAQ:ZVRA) Price Target Lowered to $23.00 at Guggenheim - MarketBeat
3.66%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):